Last update:

Clinical pharmacology news

Ultrasound turns anticancer molecule into deep-lung bacteria killer

An anticancer medication called TLD1433, a ruthenium(II) complex that has entered Phase II trials for conditions such as non-muscle-invasive bladder cancer, is now being repurposed to address one of the biggest public health ...

New map reveals how antidepressants reshape the brain's serotonin system

A new study has uncovered how antidepressants affect different groups of serotonin-producing brain cells in opposite ways, offering new insights into why selective serotonin reuptake inhibitors (SSRIs) can cause unpleasant ...

Hay fever, antihistamines and the evidence on dementia risk

For millions of people around the world, pollen season means weeks of sneezing, itchy eyes, and a blocked or runny nose. The timing varies depending on where you live and which plants are in flower, but grass pollen is one ...

Africa races for Ebola vaccine as outbreak outpaces response

Researchers racing to develop a vaccine to fight the growing Ebola outbreak centered in the Democratic Republic of the Congo (DRC) say doses could be ready for human testing within "two to three months," while the more promising ...

Flu drugs show promise against cognitive decline

A class of flu drugs may reduce cognitive decline and premature aging in people living with chronic viral infection, reports a new study led by Northwestern University that began with blood samples from people with HIV and ...

Study identifies new treatment targets for vascular dementia

A new study led by researchers at UNSW Sydney's Center for Healthy Brain Aging (CHeBA) has identified potential biological targets that could help guide future research into treatments for vascular dementia—a common and serious ...

TBI survivors turn to psychedelics for symptom relief

A new study from the University of Victoria (UVic) has identified a segment of traumatic brain injury survivors who are using psychedelics to self-medicate for cognitive, mood and somatic symptoms such as headaches. In a ...

Semaglutide improves vascular responsiveness to insulin

Glucagon-like peptide-1 receptor agonists, known as GLP-1 drugs, are highly effective at helping people lose weight and substantially lower the risk of heart attacks, strokes, and death from heart disease. A new study conducted ...

Weight-loss drugs could tackle Alzheimer's—study

A new study has found comprehensive evidence that "weight-loss" GLP-1 receptor agonists such as semaglutide are effective in tackling the biological drivers of Alzheimer's disease. The study, published in the journal Molecular ...

New cellular target prevents hepatitis E infection

An international team of researchers has identified a promising new approach for treating infections with the Hepatitis E virus (HEV). At the center of the study is the drug Apilimod, which specifically blocks the entry of ...